Sign in to view content

Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study

Ananda Kalevar, MD, FRCS(C), DABO

Video
Published 2020

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Benefits and Value of Treatment for Diabetic Macular Edema
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2022
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial
Maziar Lalezary, MD, FASRS
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more